Pluri IncNASDAQ:PLURNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.5900
- TODAY'S CHANGE (%)0.0029 (0.4940%)
- Bid / Lots0.5602/ 12
- Ask / Lots0.6200/ 12
- Open / Previous Close0.5879 / 0.5871
- Day Range
- 52 Week Range
- Volume43,508
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PLUR |
|---|---|---|
| 09:32 ET | 2395 | 0.5773 |
| 09:56 ET | 4200 | 0.5602 |
| 10:14 ET | 300 | 0.5603 |
| 10:35 ET | 2138 | 0.5503 |
| 10:39 ET | 100 | 0.55 |
| 10:48 ET | 700 | 0.5599 |
| 10:55 ET | 1000 | 0.587599 |
| 11:06 ET | 2069 | 0.59 |
| 11:09 ET | 5833 | 0.59 |
| 11:20 ET | 150 | 0.593465 |
| 11:24 ET | 660 | 0.59 |
| 12:14 ET | 100 | 0.5998 |
| 12:38 ET | 233 | 0.59 |
| 01:03 ET | 14350 | 0.592206 |
| 01:21 ET | 500 | 0.56 |
| 01:57 ET | 2475 | 0.56 |
| 02:58 ET | 100 | 0.59 |
| 03:05 ET | 100 | 0.59 |
| 03:57 ET | 2500 | 0.574949 |
| 03:59 ET | 2820 | 0.59 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Pluri Inc | 24.3M | -0.7x | --- |
Goldenwell Biotech Inc | 24.8M | -24.5x | --- |
NLS Pharmaceutics AG | 24.6M | -0.8x | --- |
Bioxytran Inc | 23.9M | -7.1x | --- |
Purple Biotech Ltd | 23.7M | -0.4x | --- |
MyMD Pharmaceuticals Inc | 23.4M | -1.6x | --- |
Company Information
Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company's products include PLX-PAD and PLX R18. The Company's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company's PLX products are administered using a standard needle and syringe. The Company's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.
Contact Information
- Headquarters
- Matam Park Building 5HAIFA, Israel 3508409
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Zalman Aberman
- President, Chief Executive Officer, Director
- Yaky Yanay
- Chief Financial Officer, Treasurer, Secretary
- Chen Franco-Yehuda
- Director
- Lorne Abony
- Independent Director
- Doron Birger
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $24.3M |
|---|---|
Revenue (TTM) | $287.0K |
Shares Outstanding | 41.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.54 |
EPS | $-0.80 |
Book Value | $0.32 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | 84.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -9,493.38% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
